Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenzilumab - Humanigen

Drug Profile

Lenzilumab - Humanigen

Alternative Names: Humaneered® anti-human GM-CSF monoclonal Antibody; KB-003; LENZ®

Latest Information Update: 29 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KaloBios Pharmaceuticals
  • Developer Humanigen; KaloBios Pharmaceuticals; Kite Pharma; National Institute of Allergy and Infectious Diseases; Peter MacCallum Cancer Centre
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Cytokine release syndrome
  • Phase III COVID 2019 infections
  • Phase II/III Graft-versus-host disease
  • Phase II Chronic myelomonocytic leukaemia
  • Phase I/II Drug hypersensitivity
  • No development reported Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Discontinued Asthma; B-cell lymphoma; Rheumatoid arthritis

Most Recent Events

  • 27 Mar 2024 Humanigen completes a phase I trials in COVID-2019 infections (In volunteers) in South Korea (IV)
  • 27 Mar 2024 Pharmacokinetic and adverse events data from a phase I trial in healthy volunteers presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2024)
  • 03 Jan 2024 Taran Therapeutics plans to acquire lenzilumab
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top